BNGO
Bionano Genomics, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$1.73
−0.57%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.75
From 52W high−18.78%
Volume1.19M
Market cap$20.37M
P/E (TTM)—
P/S (TTM)0.7x
Div yield—
Key dataSep 18, 2026
Open
$1.75
From 52W high
−18.78%
Volume
1.19M
Market cap
$20.37M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.8x
P/E (TTM)
—
RSI (14)
80.0
MomentumView details →
1D Return
−0.57%
YTD Return
+13.40%
SummaryUpdated Jun 1, 2026
Bionano Genomics, Inc. (NASDAQ:BNGO) is a medical diagnostics and research company founded in 2003 and headquartered in San Diego, California. The company went public in August 2018 and specializes in genome analysis software solutions, particularly through its flagship <b>Optical Genome Mapping (OGM)</b> technology. Originally focused on aggressive growth and customer acquisition, Bionano has undergone significant strategic restructuring since 2024, pivoting from expansion to profitability by dramatically reducing its workforce from over 400 to under 125 employees and focusing on supporting its existing customer base of routine users.
Similar companies
Latest newsMore news →
Three new peer-reviewed studies from independent research teams at MD Anderson Cancer Center, the University of Oulu, and the Josep Carreras Leukaemia Research Institute demonstrated the clinical value of Bionano's optical genome mapping in myelodysplastic syndromes and acute myeloid leukemia.6d agoBionano Laboratories received approval from the New York State Department of Health for its optical genome mapping-based lab developed tests, enabling clinical use at University of Rochester Medicine.12d agoBionano Genomics, Inc. held its Q2 2026 earnings call on August 10, 2026.41d ago